Location: San Diego

R&D Focus: Autoimmune and inflammatory diseases; initially, acute graft-versus-host disease, severe asthma and lupus nephritis

Founded: 2017

Founders: Chairman and CEO Daniel Bradbury, president and chief business officer Bruce Steel, and chief scientific officer Stephen Connelly

Employees: 16

Financing To Date: $81m, including $9.4m in seed financing via convertible notes and $71.6m in gross proceeds from an October 2018 IPO. The company's cash and investments totaled $61.6m as of 31 March.

Investors: Immediately following the IPO, the largest shareholders were Bradbury (22%), Steel (22%), Biocon (13.7%) and Connelly (7.7%).

Equillium Will Study In-Licensed Itolizumab In Three Indications In 2019

More from Strategy

More from Business